COSENTYX® Clinical Study Experience
TRANSFIGURE study
Reich K, et al. Secukinumab shows high and sustained efficacy in nail psoriasis: 2.5-year results from the randomized placebo-controlled TRANSFIGURE study. Br J Dermatol 2021;184:425–436.
EXCEED study
McInnes IB, Behrens F, Mease PJ, et al. Secukinumab versus adalimumab for treatment of active psoriatic arthritis (EXCEED): a double-blind, parallel-group, randomized, active-controlled, phase 3b trial. Lancet. 2020;395:1496–1505.
FUTURE 1 study
Philip J. Mease, et al. Secukinumab Inhibition of Interleukin-17A in Patients with Psoriatic Arthritis. N Engl J Med 2015; 373:1329-1339.
FUTURE 2 study
McInnes IB, et al. Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2015;386(9999)1137–1146.
FUTURE 2 study – 2 year data
McInnes IB, et al. Secukinumab sustains improvement in signs and symptoms of psoriatic arthritis: 2 year results from the phase 3 FUTURE 2 study. Rheumatol 2017;56:1993-2003.
FUTURE 5 study
Mease P, et al. Secukinumab improves active psoriatic arthritis symptoms and inhibits radiographic progression: primary results from the randomised, double-blind, phase III FUTURE 5 study. Ann Rheum Dis. 2018;77(6):890–897.
FUTURE 5 study – 2 year data
Mease PJ, et al. Secukinumab provides sustained improvement in signs and symptoms and low radiographic progression in patients with psoriatic arthritis: 2-year (end-of- study) results from the FUTURE 5 study. RMD Open 2021;7:e001600.
MAXIMISE study
Baraliakos X, et al. Secukinumab in patients with psoriatic arthritis and axial manifestations: results from the double-blind, randomised, phase 3 MAXIMISE trial. Ann Rheum Dis. 2021;80(5):582–590.
MEASURE 1 + 2 studies
Baeten D, et al. Secukinumab, an interleukin-17A inhibitor, in ankylosing spondylitis. N Engl J Med. 2015;373(26):2534–2548.
MEASURE 1 – 5 year data
Baraliakos X, et al. Long-term efficacy and safety of secukinumab 150 mg in ankylosing spondylitis: 5-year results from the phase III MEASURE 1 extension study. RMD Open 2019;5:e001005.
MEASURE 2 – 5 year data
Marzo-Ortega, H., et al. 5-year efficacy and safety of secukinumab in patients with ankylosing spondylitis: end-of-study results from the phase 3 MEASURE 2 trial. Lancet Rheum. 2020;2(6):e339–e346.
MEASURE 3
Pavelka K, et al. Efficacy, safety, and tolerability of secukinumab in patients with active ankylosing spondylitis: a randomized, double-blind phase 3 study, MEASURE 3. Arthritis Res Ther. 2017;19(1):285.
MEASURE 3 – 3 year data
Pavelka K, et al. Secukinumab 150/300 mg Provides Sustained Improvements in the Signs and Symptoms of Active Ankylosing Spondylitis: 3-Year Results from the Phase 3 MEASURE 3 Study. ACR Open Rheumatol. 2020;2(2):119-127.
PREVENT study
Deodhar A, et al. Improvement of signs and symptoms of nonradiographic axial spondyloarthritis in patients treated with secukinumab: Primary results of a randomized, placebo-controlled phase III study. Arthritis Rheumatol. 2021;73(1):110–120.
JUNIPERA study
Brunner H, et al. Secukinumab in enthesitis-related and juvenile psoriatic arthritis: a randomised, double-blind, placebo-controlled, withdrawal, phase3 trial. Ann Rheum Dis Epub ahead of print: [3 Nov 2022]. doi:10.1136/annrheumdis-2022-222849.
CLEAR study
Blauvelt A, et al. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to-severe plaque psoriasis up to 1 year: Results from the CLEAR study. J Am Acad Dermatol 2017;76(1):60-69.e9.
SCALP study
Bagel J, et al. The effect of secukinumab on moderate-to-severe scalp psoriasis: Results of a 24-week, randomized, double-blind, placebo-controlled phase 3b study. J am Acad Dermatol 201;77(4):667-674.
* Clinical significance unknown.
COSENTYX® is indicated for the treatment of:
- Moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy.
- Moderate to severe plaque psoriasis in pediatric patients 6 years and older who are candidates for systemic therapy or phototherapy.
- Active psoriatic arthritis in adult patients when the response to previous disease-modifying anti-rheumatic drug (DMARD) therapy has been inadequate. COSENTYX® can be used alone or in combination with methotrexate.
- Active ankylosing spondylitis in adult patients who have responded inadequately to conventional therapy.
- Active non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated C-reactive protein (CRP) and/or magnetic resonance imaging (MRI) evidence in adults who have responded inadequately, or are intolerant to nonsteroidal anti-inflammatory drugs (NSAIDs).
- Juvenile idiopathic arthritis categories:
- Active enthesitis-related arthritis in patients 6 years and older whose disease has responded inadequately to, or who cannot tolerate, conventional therapy.
- Active juvenile psoriatic arthritis in patients 6 years and older whose disease has responded inadequately to, or who cannot tolerate, conventional therapy.
- Moderate to severe hidradenitis suppurativa (acne inversa) in adult patients who have responded inadequately to conventional systemic hidradenitis suppurativa therapy.
Consult the Product Monograph at www.novartis.ca/CosentyxMonograph for important information relating to adverse reactions, drug interactions, and dosing information which have not been discussed in this piece. The Product Monograph is also available by calling 1-800-363-8883.
References
- COSENTYX® Product Monograph. Novartis Pharmaceuticals Canada Inc.
- Data on file. Novartis Pharmaceuticals Canada Inc.
COSENTYX and SensoReady are registered trademarks.
Product Monograph available on request
431035E
© Novartis Pharmaceuticals Canada Inc. January 2025
Related content
Patient Support Program
Patient Support Program
Get tailored support for you and your COSENTYX® patients.